Antischizophrenic drugs: Differential plasma protein binding and therapeutic activity

Kenneth A. Freedberg, Robert B. Innis, Ian Creese, Solomon H Snyder

Research output: Contribution to journalArticle

Abstract

The percentage of free neuroleptic drug unbound to plasma protein is much higher for the respective metabolites of chlorpromazine and thioridazine, 7-hydroxychlorpromazine and mesoridazine, than for the parent drugs. The therapeutic activities of chlorpromazine and thioridazine may be mediated to a major extent by 7-hydroxychlorpromazine and mesoridazine respectively. Measuring free levels of the active metabolites of neuroleptics as well as the parent drugs may facilitate regulation of neuroleptic doses to secure optimal therapeutic responses.

Original languageEnglish (US)
Pages (from-to)2467-2473
Number of pages7
JournalLife Sciences
Volume24
Issue number26
DOIs
StatePublished - Jun 25 1979

Fingerprint

Mesoridazine
Protein Binding
Antipsychotic Agents
Thioridazine
Blood Proteins
Chlorpromazine
Metabolites
Pharmaceutical Preparations
Therapeutics
7-hydroxychlorpromazine

ASJC Scopus subject areas

  • Pharmacology

Cite this

Antischizophrenic drugs : Differential plasma protein binding and therapeutic activity. / Freedberg, Kenneth A.; Innis, Robert B.; Creese, Ian; Snyder, Solomon H.

In: Life Sciences, Vol. 24, No. 26, 25.06.1979, p. 2467-2473.

Research output: Contribution to journalArticle

Freedberg, Kenneth A. ; Innis, Robert B. ; Creese, Ian ; Snyder, Solomon H. / Antischizophrenic drugs : Differential plasma protein binding and therapeutic activity. In: Life Sciences. 1979 ; Vol. 24, No. 26. pp. 2467-2473.
@article{0d6d39b10f7b4ab08f592a313d4bfa92,
title = "Antischizophrenic drugs: Differential plasma protein binding and therapeutic activity",
abstract = "The percentage of free neuroleptic drug unbound to plasma protein is much higher for the respective metabolites of chlorpromazine and thioridazine, 7-hydroxychlorpromazine and mesoridazine, than for the parent drugs. The therapeutic activities of chlorpromazine and thioridazine may be mediated to a major extent by 7-hydroxychlorpromazine and mesoridazine respectively. Measuring free levels of the active metabolites of neuroleptics as well as the parent drugs may facilitate regulation of neuroleptic doses to secure optimal therapeutic responses.",
author = "Freedberg, {Kenneth A.} and Innis, {Robert B.} and Ian Creese and Snyder, {Solomon H}",
year = "1979",
month = "6",
day = "25",
doi = "10.1016/0024-3205(79)90457-0",
language = "English (US)",
volume = "24",
pages = "2467--2473",
journal = "Life Sciences",
issn = "0024-3205",
publisher = "Elsevier Inc.",
number = "26",

}

TY - JOUR

T1 - Antischizophrenic drugs

T2 - Differential plasma protein binding and therapeutic activity

AU - Freedberg, Kenneth A.

AU - Innis, Robert B.

AU - Creese, Ian

AU - Snyder, Solomon H

PY - 1979/6/25

Y1 - 1979/6/25

N2 - The percentage of free neuroleptic drug unbound to plasma protein is much higher for the respective metabolites of chlorpromazine and thioridazine, 7-hydroxychlorpromazine and mesoridazine, than for the parent drugs. The therapeutic activities of chlorpromazine and thioridazine may be mediated to a major extent by 7-hydroxychlorpromazine and mesoridazine respectively. Measuring free levels of the active metabolites of neuroleptics as well as the parent drugs may facilitate regulation of neuroleptic doses to secure optimal therapeutic responses.

AB - The percentage of free neuroleptic drug unbound to plasma protein is much higher for the respective metabolites of chlorpromazine and thioridazine, 7-hydroxychlorpromazine and mesoridazine, than for the parent drugs. The therapeutic activities of chlorpromazine and thioridazine may be mediated to a major extent by 7-hydroxychlorpromazine and mesoridazine respectively. Measuring free levels of the active metabolites of neuroleptics as well as the parent drugs may facilitate regulation of neuroleptic doses to secure optimal therapeutic responses.

UR - http://www.scopus.com/inward/record.url?scp=0018743954&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018743954&partnerID=8YFLogxK

U2 - 10.1016/0024-3205(79)90457-0

DO - 10.1016/0024-3205(79)90457-0

M3 - Article

C2 - 39211

AN - SCOPUS:0018743954

VL - 24

SP - 2467

EP - 2473

JO - Life Sciences

JF - Life Sciences

SN - 0024-3205

IS - 26

ER -